Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Small cell lung cancer (SCLC) presents limited therapeutic avenues, driving research into novel treatments.
• Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting delta-like 3 (DLL3) on SCLC cells.
• Assessing the cardiac safety of novel oncology drugs is critical for patient well-being.

Purpose of the Study:

• To evaluate the cardiac safety profile of Rovalpituzumab tesirine (Rova-T) in patients with previously treated extensive-stage SCLC.
• To assess the impact of Rova-T on QT interval, ECG waveforms, heart rate, and proarrhythmic adverse events.
• To determine if Rova-T administration leads to clinically significant cardiac safety concerns.

Main Methods:

• Prospective evaluation of cardiac safety in 46 patients with previously treated extensive-stage SCLC.
• Electrocardiogram (ECG) monitoring for 2 weeks post-infusion following Rova-T treatment (0.3 mg/kg IV every 6 weeks).
• Analysis included QT interval (QTcF), QRS, PR intervals, ECG waveforms, heart rate, and adverse events.

Main Results:

• No significant changes in Fridericia-corrected QT (QTcF) interval were observed at Rova-T's maximum serum concentration.
• No clinically significant alterations in QRS or PR intervals, ECG waveforms, or heart rate were detected.
• While all patients experienced treatment-emergent adverse events (TEAEs), proarrhythmic tendencies were uncommon.

Conclusions:

• Rovalpituzumab tesirine (Rova-T) administration at 0.3 mg/kg IV every 6 weeks can be considered safe regarding cardiac electrical activity.
• A QTcF effect of clinical concern can be excluded based on the evaluated ECG data.
• Further research into Rova-T's efficacy and safety in SCLC is warranted.